江苏恒瑞医药股份有限公司第九届董事会第二十次会议决议公告

Core Points - The board of directors of Jiangsu Hengrui Medicine Co., Ltd. held its 20th meeting of the 9th session on December 3, 2025, and unanimously approved the nomination of Mr. Zhu Guoxin as the Senior Vice President of the company [1][3] - Mr. Zhu Guoxin has over 30 years of global cross-functional drug discovery leadership experience, covering various stages from target hypothesis to early clinical testing, with expertise in diabetes/obesity and its complications, immunology, neurological diseases, pain, and oncology [1][2] Summary by Sections - Board Meeting Details - The meeting was conducted via communication means with all 11 directors present, complying with the Company Law and Articles of Association [1] - The proposal to appoint Mr. Zhu Guoxin was reviewed and approved by the board's nomination committee [3] - Mr. Zhu Guoxin's Background - Prior to joining the company, Mr. Zhu served as Vice President at Eli Lilly's drug development center, leading multiple discovery and early development projects [2] - He has a strong academic background, holding a bachelor's degree from Zhejiang University, a master's and Ph.D. from Shanghai Institute of Organic Chemistry, and completed postdoctoral research at Pennsylvania State University [2]